Articles from ViaLase, Inc.

ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide.

ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe.

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A. Moran Eye Center at the University of Utah (Moran Eye Center), home to the renowned Alan S. Crandall Center for Glaucoma Innovation (Crandall Center). The collaboration will explore aqueous outflow dynamics of ViaLase’s novel ViaLase laser procedure, utilizing Moran’s state-of-the-art iPerfusion technology.